Developer docs
API playgroundTry for free, no card

Search company profiles

DNA Electronics

Full company profile

uuid00088ko

Namestring
DNA Electronics
Legal namestring
DNAe Group Holdings Limited
Websiteurl
dnae.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

DNA Electronics (DNAe) is a molecular diagnostics company founded in 2003 as a spin-out from Imperial College London, developing the LiDia-SEQ platform — described as the world's first fully automated, sample-to-report next-generation sequencing (NGS) diagnostic system. The platform is built on proprietary semiconductor sequencing technology invented by co-founder Professor Christofer Toumazou, which detects protons released during DNA synthesis on a silicon-chip based transistor, enabling an optics-free, label-free, compact benchtop device operable by non-specialist users at the point-of-need. The flagship assay is a bloodstream infection and antimicrobial resistance (BSI/AMR) test that delivers pathogen identification directly from whole blood in approximately 3-4 hours, compared to 2-6 days for traditional blood culture, covering roughly 7,400 bacterial species, ~800 fungal species, and 26 AMR markers. A development pipeline extends the platform into oncology (circulating tumor DNA liquid biopsy, including a Specific Variant Capture method) and viral detection.

DNAe operates a platform-plus-consumables revenue model: the LiDia-SEQ instrument is sold or leased to hospitals, STAT labs, and clinical facilities, with recurring revenue from proprietary test cartridges and accompanying software that produces diagnostic reports. The go-to-market is enterprise field sales targeting large hospital systems and academic medical centers, supported by an Early Access Program (launched December 2025) and presence at major scientific conferences. The company is pre-commercial — initial commercial launch is targeted for early 2027 in North America and the UK for research use only, with phased European rollout followed by expansion into Asia and the Middle East. Revenue is not disclosed; the company has been funded primarily through a BARDA contract worth up to $51.9 million (awarded September 2016) and is backed by Genting Berhad as a major shareholder. The LiDia-SEQ system and BSI/AMR test received FDA Breakthrough Device designation in April 2020.

Short descriptiontext

DNA Electronics (DNAe) is a pre-commercial molecular diagnostics company developing the LiDia-SEQ platform, a fully automated semiconductor NGS system enabling rapid point-of-need pathogen and oncology testing for hospitals and clinical laboratories.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
semiconductor sequencing diagnostics, molecular diagnostics platform, bloodstream infection testing, antimicrobial resistance diagnostics, point-of-care genomics
Industry2 codes
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Molecular Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Platform (LiDia-SEQ System) Sales/Leasing
TypeHardware Sales
Description

DNAe generates revenue from the sale or leasing of its LiDia-SEQ benchtop sequencing system/devices to hospitals, STAT labs, and clinical facilities. The system is a desktop device deployable at the point-of-need, operated by non-technical staff.

dnae.com
2Diagnostic Test Kits (Consumables)
TypeHardware Sales
Description

Revenue is generated from the sale of proprietary test kits (consumable cartridges) used with the LiDia-SEQ platform. Tests include the BSI/AMR test, oncology/cancer monitoring tests, and a growing pipeline of follow-on tests. The platform consists of the system, test kits, and software.

dnae.com
3Software / Diagnostic Reporting
TypeSubscription Recurring
Description

Revenue is generated from the software component of the LiDia-SEQ platform which provides clinically actionable diagnostic reports output to clinicians, as part of the integrated platform offering.

dnae.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1LiDia-SEQ™
Description

Direct-from-specimen diagnostic system that performs DNA sequencing on a microchip, providing rapid, actionable information to clinicians. The world's first fully automated NGS-based diagnostic platform for bloodstream infections, oncology, and antimicrobial resistance detection.

dnae.com
Core offering1 text field

DNAe develops and manufactures the LiDia-SEQ Platform, a benchtop DNA sequencing system that performs rapid, fully automated next-generation sequencing on disposable semiconductor microchip cartridges. Its first commercial assay is the BSI/AMR Test, designed to identify bloodstream infections and antimicrobial resistance markers directly from whole blood in approximately three to four hours, intended for use in hospital and clinical laboratory settings without requiring specialist molecular biology expertise.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Results delivered in 3-4 hours vs. 2-6 days for traditional blood culture testing
+3 more records
Product overview1 text field

DNA Electronics (DNAe) is developing the LiDia-SEQ™ Platform as its core product — a direct-from-specimen, fully automated semiconductor sequencing diagnostic system that performs DNA sequencing on a microchip to deliver rapid, actionable genomic information at the point-of-need. The platform hosts multiple tests including the BSI/AMR Test (the first commercially targeted assay for bloodstream infections and antimicrobial resistance detection from whole blood in 3-4 hours), oncology/cancer tests using liquid biopsy and circulating tumor DNA (ctDNA) analysis, and viral detection tests in the pipeline. The portfolio also includes the proprietary Specific Variant Capture (SVC) method for ctDNA enrichment. This represents a unified platform-plus-tests architecture where the LiDia-SEQ™ system and test kits work together to provide sample-to-result diagnostics across infectious disease and oncology applications.

Product and service1 record
1LiDia-SEQ Platform
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierSignificantTypeStrategic or Co-development PartnerAnnounced on2021-10-27
Description

DNAe, Imperial College London, and the University of Leicester were awarded a UK Knowledge Transfer Partnership (KTP) by Innovate UK to develop an NGS-based liquid biopsy test for early detection of recurrent breast cancer. Professor Jacqui Shaw from Leicester contributes expertise in circulating tumor DNA and translational cancer genetics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

DNAe was founded as a spin-out from Imperial College London in 2003 by Regius Professor Christofer Toumazou. Professor Toumazou remains Executive Chairman and Founder. DNAe relocated its UK headquarters to Scale Space, a partnership between Imperial College London and Blenheim Chalcot. The company maintains ongoing research partnerships with Imperial faculty.

3Professor Charles Coombes (Imperial College London)
Strategic tierSignificantTypeStrategic or Co-development Partner
Description

Professor Charles Coombes, Professor of Medical Oncology at Imperial College London and Honorary Consultant Medical Oncologist, leads the academic side of the KTP collaboration on breast cancer liquid biopsy testing. His research in using circulating tumor DNA to manage breast cancer treatment is being integrated into DNAe's diagnostic platform.

dnae.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

DNAe relocated its UK operations to Scale Space in 2019/2020 — a partnership between Imperial College London and Blenheim Chalcot. Scale Space provides office and laboratory facilities near the White City innovation hub.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

GeneXpert systems are the dominant rapid molecular diagnostics platform in hospitals globally, including for BSI-related applications; large installed base, menu breadth, and hospital workflow integration make Cepheid a primary reference competitor for DNAe's commercialization.

TypeDirect peer
Description

Pioneered a fundamentally novel, non-optical NGS architecture (nanopore-based detection of DNA); while chemistry differs, both Oxford Nanopore and DNAe share the strategic positioning of alternative-architecture sequencing platforms competing with optical/Illumina-style NGS in infectious disease and oncology use cases.

TypeDirect peer
Description

BioFire FilmArray Blood Culture Identification panels and broader syndromic molecular diagnostics franchise target the same hospital microbiology customers and rapid ID/AST workflows that LiDia-SEQ's BSI/AMR assay addresses.

TypeBroad incumbent
Description

Dominant NGS incumbent whose benchtop (NextSeq, iSeq) and larger instruments, reagents, and IVD partnerships underpin most clinical sequencing workflows; relevant as the broader competitive backdrop and potential partner for DNAe's oncology applications.

TypeEmerging player
Description

Cell-free DNA-based infectious disease diagnostics (Karius Test) for rapid pathogen identification from blood, including for immunocompromised and sepsis patients; a smaller commercial-stage emerging player addressing the same clinical use case from a different technological angle.

TypeDirect peer
Description

QIAstat-Dx is a cartridge-based, sample-to-result real-time PCR syndromic diagnostics system targeting hospital point-of-need infectious disease testing, closely comparable to DNAe's benchtop, cartridge-contained automated approach and target customer.

TypeDirect peer
Description

Accelerate Pheno system provides rapid identification and antimicrobial susceptibility testing directly from positive blood cultures — addressing the same BSI/AMR clinical decision-point and competing for the same hospital microbiology budgets as DNAe's LiDia-SEQ.

TypeDirect peer
Description

ePlex and other cartridge-based molecular diagnostic systems targeting hospital syndromic and infectious-disease testing; comparable benchtop, cartridge-platform business model and customer base to DNAe's LiDia-SEQ (now part of Roche).

TypeDirect peer
Description

Direct competitor in rapid molecular diagnostics for bloodstream infections and sepsis; T2Bacteria and T2Candida panels deliver species ID directly from whole blood without blood culture, making T2 the most head-to-head comp to DNAe's BSI/AMR test.

TypeBroad incumbent
Description

Long-read NGS platform (HiFi sequencing via SMRT technology); relevant as another alternative-architecture sequencing competitor and as a comparable benchtop sequencing-platform company with infectious-disease and oncology ambitions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DNA Electronics

Molecular Diagnosticsdnae.com

DNA Electronics (DNAe) is a pre-commercial molecular diagnostics company developing the LiDia-SEQ platform, a fully automated semiconductor NGS system enabling rapid point-of-need pathogen and oncology testing for hospitals and clinical laboratories.

What DNA Electronics does

DNA Electronics (DNAe) is a molecular diagnostics company founded in 2003 as a spin-out from Imperial College London, developing the LiDia-SEQ platform — described as the world's first fully automated, sample-to-report next-generation sequencing (NGS) diagnostic system. The platform is built on proprietary semiconductor sequencing technology invented by co-founder Professor Christofer Toumazou, which detects protons released during DNA synthesis on a silicon-chip based transistor, enabling an optics-free, label-free, compact benchtop device operable by non-specialist users at the point-of-need. The flagship assay is a bloodstream infection and antimicrobial resistance (BSI/AMR) test that delivers pathogen identification directly from whole blood in approximately 3-4 hours, compared to 2-6 days for traditional blood culture, covering roughly 7,400 bacterial species, ~800 fungal species, and 26 AMR markers. A development pipeline extends the platform into oncology (circulating tumor DNA liquid biopsy, including a Specific Variant Capture method) and viral detection.

DNAe operates a platform-plus-consumables revenue model: the LiDia-SEQ instrument is sold or leased to hospitals, STAT labs, and clinical facilities, with recurring revenue from proprietary test cartridges and accompanying software that produces diagnostic reports. The go-to-market is enterprise field sales targeting large hospital systems and academic medical centers, supported by an Early Access Program (launched December 2025) and presence at major scientific conferences. The company is pre-commercial — initial commercial launch is targeted for early 2027 in North America and the UK for research use only, with phased European rollout followed by expansion into Asia and the Middle East. Revenue is not disclosed; the company has been funded primarily through a BARDA contract worth up to $51.9 million (awarded September 2016) and is backed by Genting Berhad as a major shareholder. The LiDia-SEQ system and BSI/AMR test received FDA Breakthrough Device designation in April 2020.

DNA Electronics firmographics

Firmographics
Name
DNA Electronics
Legal name
DNAe Group Holdings Limited
Website
https://dnae.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
101–250 employees
Short description
DNA Electronics (DNAe) is a pre-commercial molecular diagnostics company developing the LiDia-SEQ platform, a fully automated semiconductor NGS system enabling rapid point-of-need pathogen and oncology testing for hospitals and clinical laboratories.
Ownership category
akta.pro rank

DNA Electronics industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Semiconductor sequencing diagnostics
  • Molecular diagnostics platform
  • Bloodstream infection testing
  • Antimicrobial resistance diagnostics
  • Point-of-care genomics

Where DNA Electronics is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

DNA Electronics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Diagnostic Platform (LiDia-SEQ System) Sales/Leasing: DNAe generates revenue from the sale or leasing of its LiDia-SEQ benchtop sequencing system/devices to hospitals, STAT labs, and clinical facilities. The system is a desktop device deployable at the point-of-need, operated by non-technical staff.
  2. Diagnostic Test Kits (Consumables): Revenue is generated from the sale of proprietary test kits (consumable cartridges) used with the LiDia-SEQ platform. Tests include the BSI/AMR test, oncology/cancer monitoring tests, and a growing pipeline of follow-on tests. The platform consists of the system, test kits, and software.
  3. Software / Diagnostic Reporting: Revenue is generated from the software component of the LiDia-SEQ platform which provides clinically actionable diagnostic reports output to clinicians, as part of the integrated platform offering.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

DNA Electronics product offering

Product offering

Core offering

DNAe develops and manufactures the LiDia-SEQ Platform, a benchtop DNA sequencing system that performs rapid, fully automated next-generation sequencing on disposable semiconductor microchip cartridges. Its first commercial assay is the BSI/AMR Test, designed to identify bloodstream infections and antimicrobial resistance markers directly from whole blood in approximately three to four hours, intended for use in hospital and clinical laboratory settings without requiring specialist molecular biology expertise.

Product overview

DNA Electronics (DNAe) is developing the LiDia-SEQ™ Platform as its core product — a direct-from-specimen, fully automated semiconductor sequencing diagnostic system that performs DNA sequencing on a microchip to deliver rapid, actionable genomic information at the point-of-need. The platform hosts multiple tests including the BSI/AMR Test (the first commercially targeted assay for bloodstream infections and antimicrobial resistance detection from whole blood in 3-4 hours), oncology/cancer tests using liquid biopsy and circulating tumor DNA (ctDNA) analysis, and viral detection tests in the pipeline. The portfolio also includes the proprietary Specific Variant Capture (SVC) method for ctDNA enrichment. This represents a unified platform-plus-tests architecture where the LiDia-SEQ™ system and test kits work together to provide sample-to-result diagnostics across infectious disease and oncology applications.

Differentiator

Problem solved

Functional benefit

Brands

  • LiDia-SEQ™: Direct-from-specimen diagnostic system that performs DNA sequencing on a microchip, providing rapid, actionable information to clinicians. The world's first fully automated NGS-based diagnostic platform for bloodstream infections, oncology, and antimicrobial resistance detection.

Products and services

  • LiDia-SEQ Platform

Quantifiable outcome

  • Results delivered in 3-4 hours vs. 2-6 days for traditional blood culture testing
  • +3 more outcomes

Companies that use DNA Electronics

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

DNA Electronics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

DNA Electronics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered significant, core and supporting.

  • University of LeicestersignificantStrategic or Co-development Partner · 27 October 2021DNAe, Imperial College London, and the University of Leicester were awarded a UK Knowledge Transfer Partnership (KTP) by Innovate UK to develop an NGS-based liquid biopsy test for early detection of recurrent breast cancer. Professor Jacqui Shaw from Leicester contributes expertise in circulating tumor DNA and translational cancer genetics.
  • Imperial College LondoncoreStrategic or Co-development PartnerDNAe was founded as a spin-out from Imperial College London in 2003 by Regius Professor Christofer Toumazou. Professor Toumazou remains Executive Chairman and Founder. DNAe relocated its UK headquarters to Scale Space, a partnership between Imperial College London and Blenheim Chalcot. The company maintains ongoing research partnerships with Imperial faculty.
  • Professor Charles Coombes (Imperial College London)significantStrategic or Co-development PartnerProfessor Charles Coombes, Professor of Medical Oncology at Imperial College London and Honorary Consultant Medical Oncologist, leads the academic side of the KTP collaboration on breast cancer liquid biopsy testing. His research in using circulating tumor DNA to manage breast cancer treatment is being integrated into DNAe's diagnostic platform.
  • Scale Space (Imperial College London / Blenheim Chalcot Joint Venture)supportingStrategic or Co-development PartnerDNAe relocated its UK operations to Scale Space in 2019/2020 — a partnership between Imperial College London and Blenheim Chalcot. Scale Space provides office and laboratory facilities near the White City innovation hub.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

DNA Electronics competitors and assessment

Company assessment

Direct peers

  • Cepheid (Danaher): GeneXpert systems are the dominant rapid molecular diagnostics platform in hospitals globally, including for BSI-related applications; large installed base, menu breadth, and hospital workflow integration make Cepheid a primary reference competitor for DNAe's commercialization.
  • Oxford Nanopore Technologies: Pioneered a fundamentally novel, non-optical NGS architecture (nanopore-based detection of DNA); while chemistry differs, both Oxford Nanopore and DNAe share the strategic positioning of alternative-architecture sequencing platforms competing with optical/Illumina-style NGS in infectious disease and oncology use cases.
  • bioMérieux (BioFire FilmArray): BioFire FilmArray Blood Culture Identification panels and broader syndromic molecular diagnostics franchise target the same hospital microbiology customers and rapid ID/AST workflows that LiDia-SEQ's BSI/AMR assay addresses.
  • QIAGEN (QIAstat-Dx): QIAstat-Dx is a cartridge-based, sample-to-result real-time PCR syndromic diagnostics system targeting hospital point-of-need infectious disease testing, closely comparable to DNAe's benchtop, cartridge-contained automated approach and target customer.
  • Accelerate Diagnostics: Accelerate Pheno system provides rapid identification and antimicrobial susceptibility testing directly from positive blood cultures — addressing the same BSI/AMR clinical decision-point and competing for the same hospital microbiology budgets as DNAe's LiDia-SEQ.
  • GenMark Diagnostics (Roche): ePlex and other cartridge-based molecular diagnostic systems targeting hospital syndromic and infectious-disease testing; comparable benchtop, cartridge-platform business model and customer base to DNAe's LiDia-SEQ (now part of Roche).
  • T2 Biosystems: Direct competitor in rapid molecular diagnostics for bloodstream infections and sepsis; T2Bacteria and T2Candida panels deliver species ID directly from whole blood without blood culture, making T2 the most head-to-head comp to DNAe's BSI/AMR test.

Broad incumbents

  • Illumina: Dominant NGS incumbent whose benchtop (NextSeq, iSeq) and larger instruments, reagents, and IVD partnerships underpin most clinical sequencing workflows; relevant as the broader competitive backdrop and potential partner for DNAe's oncology applications.
  • Pacific Biosciences: Long-read NGS platform (HiFi sequencing via SMRT technology); relevant as another alternative-architecture sequencing competitor and as a comparable benchtop sequencing-platform company with infectious-disease and oncology ambitions.

Emerging players

  • Karius: Cell-free DNA-based infectious disease diagnostics (Karius Test) for rapid pathogen identification from blood, including for immunocompromised and sepsis patients; a smaller commercial-stage emerging player addressing the same clinical use case from a different technological angle.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

DNA Electronics social profiles

Digital presence

DNA Electronics compliance and trust

Trust signal

Compliance1 record

DNA Electronics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DNA Electronics leadership team

Management profile

Number of profiles

Profiles6 records

DNA Electronics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

DNA Electronics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DNA Electronics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DNA Electronics

What does DNA Electronics do?

DNAe develops and manufactures the LiDia-SEQ Platform, a benchtop DNA sequencing system that performs rapid, fully automated next-generation sequencing on disposable semiconductor microchip cartridges. Its first commercial assay is the BSI/AMR Test, designed to identify bloodstream infections and antimicrobial resistance markers directly from whole blood in approximately three to four hours, intended for use in hospital and clinical laboratory settings without requiring specialist molecular biology expertise.

Is DNA Electronics a public or private company?

DNA Electronics is a private company. It is classified as corporate owned and is currently operating.

When was DNA Electronics founded?

DNA Electronics was founded in 2003. It employs 101 to 250 people.

Where is DNA Electronics based?

DNA Electronics is headquartered in London, United Kingdom, in the Europe region.

How does DNA Electronics make money?

Three revenue lines are on record. Diagnostic Platform (LiDia-SEQ System) Sales/Leasing is the primary driver. The others are diagnostic Test Kits (Consumables) and software / Diagnostic Reporting.

Who are DNA Electronics's main competitors?

Direct peers on record are Cepheid (Danaher), Oxford Nanopore Technologies, bioMérieux (BioFire FilmArray), QIAGEN (QIAstat-Dx), Accelerate Diagnostics, GenMark Diagnostics (Roche) and T2 Biosystems. Broad incumbents are Illumina and Pacific Biosciences. Karius is listed as an emerging player.

Does DNA Electronics have an API?

No public API is recorded for DNA Electronics.

What industry is DNA Electronics in?

DNA Electronics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR), with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireDNAe Unveils Early Access Program for LiDia‑SEQ™: Hospital Teams Invited to Trial DNAe's Flagship Tests and Preview DNAe's Innovative NGS Diagnostic PlatformDNAe, a next-generation sequencing (NGS) diagnostics company headquartered in London and Carlsbad, California, has launched an Early Access Program offering hospitals, clinics, and research institutions pre-launch access to its flagship BSI/AMR test and preview of the LiDia-SEQ™ platform. Phase One of the program begins in April 2026, enabling participants to submit whole blood samples and culture isolates to DNAe for testing, followed by on-site pilot placement of prototype LiDia-SEQ™ systems in select hospitals. The LiDia-SEQ™ platform is positioned as the world's first fully automated sample-to-report NGS diagnostic system, capable of delivering results in hours rather than days, and is currently under development without regulatory approval from the FDA or any other agency.PR NewswireDNAe Unveils Early Access Program for LiDia‑SEQ™: Hospital Teams Invited to Trial DNAe's Flagship Tests and Preview DNAe's Innovative NGS Diagnostic PlatformDNAe has launched an Early Access Program for its LiDia-SEQ™ fully automated NGS diagnostic platform, inviting hospitals and clinical partners to preview its flagship BSI/AMR test ahead of commercial launch, with Phase One testing beginning in April 2026 and prototype system placements to follow. The platform claims to be the world's first to fully automate sample-to-result diagnostics from whole blood, detecting around 7,200 bacteria, 30 antimicrobial resistance markers, and 750 fungi in hours rather than days. The company expects strong interest from teams focused on sepsis, infectious diseases, critical care, and oncology applications, with participating sites generating published data on clinical and health economic benefits.PR NewswireAMP 2025: DNAe to unveil latest data from world's first NGS-based, fully automated sample-to-result diagnostic platformDNAe announced it will present new data at the Association for Molecular Pathology (AMP) Annual Meeting in Boston from November 11-15, 2025, showcasing its LiDia-SEQ™ platform, described as the world's first fully automated, sample-to-result NGS diagnostic system for bloodstream infection detection, oncology monitoring, and antimicrobial resistance testing. The platform received FDA Breakthrough Device designation and has been developed with funding from BARDA. CEO Samuel Reed stated the company is focused on completing development of its flagship BSI/AMR test to enable rapid detection of life-threatening infections directly from whole blood samples within hours.Labiotech.euHow New Microbiome Diagnostic Technologies Can Save LivesThe article examines how emerging microbiome diagnostic technologies, such as next-generation sequencing and qPCR, are replacing traditional culture tests to provide faster and more accurate identification of microorganisms in healthcare. Key companies including Enterome, Oxford Nanopore Technologies, DNA Electronics, and IS Diagnostics are developing specific devices and tests for conditions like Crohn's disease and antibiotic resistance. These innovations aim to enable targeted treatments and predictive diagnostics to improve patient outcomes.PR NewswireIVD Counters Sepsis with InnovationsKalorama Information reports that the in vitro diagnostics (IVD) industry is advancing with multiple innovations for sepsis diagnosis, a condition that is difficult to detect early due to overlapping symptoms with other illnesses. Several biotech and diagnostic companies are developing new tests, cartridges, and platforms specifically for sepsis detection, including Atlas Genetics, Biocartis, bioMérieux, Curetis, DNA Electronics, GeneFluidics, and Immunexpress, with some products already FDA-approved and others in development.